JAK Inhibition in PReclinical Arthritis
Rheumatoid arthritis is a long-term condition that causes painful, swollen joints. Often, blood tests and minor aches show that someone is at high risk of developing it long before visible joint swelling begins. This early stage is known as the preclinical phase. This study aims to find out if starting treatment early can prevent rheumatoid arthritis from developing. Researchers are testing a daily tablet called baricitinib against a dummy tablet (a placebo) that looks identical. Adults aged 18 and over who show early risk signs can take part. Over 48 weeks, doctors will monitor participants closely using joint ultrasound scans, simple hand function tests, and blood tests. This trial will help doctors understand whether early intervention can stop joint damage before it even starts, potentially offering a new way to protect joint health in the future.
At a glance
What is this study about?
Rheumatoid arthritis is an autoimmune condition where the body's natural defence system mistakenly attacks the lining of the joints, causing pain, stiffness, and swelling. For many people, warning signs such as joint tenderness or specific antibodies in the blood appear months or years before full arthritis actually develops. Doctors call this window the 'preclinical' stage.
Currently, most treatments only start after clear joint swelling and damage have already appeared. Researchers want to know if acting sooner could protect joints before any lasting harm occurs. They are exploring whether calming down the immune system during this early stage can stop rheumatoid arthritis from developing at all.
This trial investigates a medication called baricitinib. It is already used to treat active rheumatoid arthritis by blocking signals that drive inflammation. In this Phase II study, doctors are giving baricitinib or a dummy pill (placebo) to people at high risk to see if it reduces the number of people who go on to develop arthritis over 48 weeks.
By comparing results from joint ultrasound scans, hand strength checks, and regular blood tests, this study hopes to provide clear answers on whether preventive treatment works and is safe for people at risk.
Key takeaways
- The trial tests whether the drug baricitinib can prevent rheumatoid arthritis in adults at high risk.
- Half of the participants will take baricitinib and the other half will take a dummy pill (placebo).
- Participation lasts about 48 weeks and includes regular check-ups, ultrasound scans, and blood tests.
- You must be 18 or older with early warning signs or blood markers, but no active joint swelling.
- Taking part is voluntary, and you can stop at any time without affecting your normal healthcare.
Who may be eligible?
This study is for adults aged 18 and older who are considered at high risk of developing rheumatoid arthritis, but who do not yet have full, active joint inflammation. Men and women can both take part.
Being at high risk usually means you have specific markers in your blood (such as anti-CCP antibodies) or you are experiencing mild joint aches that suggest arthritis could develop soon. The research team will run tests to confirm whether you meet the exact risk criteria.
You will not be suitable for the study if you have already been diagnosed with full rheumatoid arthritis, if you have active joint swelling, or if you have certain existing health conditions or take medicines that affect how your immune system works.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years of age or older?
- Have you been told by a doctor that you are at high risk of developing rheumatoid arthritis?
- Do you have positive blood tests for arthritis markers (such as anti-CCP antibodies)?
- Are your joints currently free from diagnosed, active rheumatoid swelling?
- Are you willing and able to take a daily tablet and attend hospital visits for 48 weeks?
What does participation involve?
Taking part lasts for around 48 weeks (just under one year). You will be randomly placed into one of two groups: one group takes a daily baricitinib tablet, and the other takes a dummy tablet (placebo) that looks identical. Neither you nor your doctor will know which tablet you are taking. You will visit the hospital or clinic regularly for check-ups, with major assessments at weeks 24 and 48. During these visits, doctors will perform painless ultrasound scans to check for hidden joint swelling, take blood samples to monitor antibody levels, and ask you to do simple tasks like picking up small objects to test hand movement. You will also complete short questionnaires about how you feel.
Potential risks and benefits
Locations (1)
- —UnverifiedGermany
Common questions
What is a placebo?
A placebo is a dummy tablet that looks and tastes identical to the real medicine but contains no active drug. It helps doctors see if the real medicine is truly effective.
Will I know if I am taking baricitinib or the placebo?
No. This is a 'double-blind' study, meaning neither you nor the study team will know which tablet you are taking until the entire study has finished.
Is baricitinib a new medicine?
Baricitinib is already approved and used routinely to treat adults with active rheumatoid arthritis. This study is testing whether using it earlier can stop the disease from starting.
What happens if my joints start swelling during the study?
The medical team will examine you promptly. If you develop full rheumatoid arthritis, the study team will stop the trial treatment and discuss standard, approved treatments to protect your joints.
Do I have to pay to take part?
No, all study tablets, scans, and tests are provided free of charge, and you may be reimbursed for travel expenses to attend your appointments.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.